Report Overview
Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Gastrointestinal Stromal Tumor (GIST) Drug market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Gastrointestinal Stromal Tumor (GIST) Drug market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Gastrointestinal Stromal Tumor (GIST) Drug market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Gastrointestinal Stromal Tumor (GIST) Drug products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Gastrointestinal Stromal Tumor (GIST) Drug products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Gastrointestinal Stromal Tumor (GIST) Drug market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Gastrointestinal Stromal Tumor (GIST) Drug development has been the leading industry trend of Gastrointestinal Stromal Tumor (GIST) Drug market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Gastrointestinal Stromal Tumor (GIST) Drug Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Amcasertib,Anagrelide hydrochloride CR,APG-1351,Binimetinib,Others |
| By Application Outlook |
Clinic,Hospital,Others |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Ariad Pharmaceuticals, Inc.,Arog Pharmaceuticals, Inc.,Array BioPharma Inc.,Astex Pharmaceuticals, Inc.,Blueprint Medicines Corporation,Boston Biomedical, Inc.,Calithera Biosciences, Inc.,Chipscreen Biosciences Ltd,Deciphera Pharmaceuticals, LLC,F. Hoffmann-La Roche Ltd.,Horizon Pharma Plc,Immunicum AB,Jiangsu Hengrui Medicine Co., Ltd.,Kolltan Pharmaceuticals, Inc.,Natco Pharma Limited,Nerviano Medical Sciences S.r.l.,Novartis AG,Omeros Corporation |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Ariad Pharmaceuticals
- Inc.
- Arog Pharmaceuticals
- Inc.
- Array BioPharma Inc.
- Astex Pharmaceuticals
- Inc.
- Blueprint Medicines Corporation
- Boston Biomedical
- Inc.
- Calithera Biosciences
- Inc.
- Chipscreen Biosciences Ltd
- Deciphera Pharmaceuticals
- LLC
- F. Hoffmann-La Roche Ltd.
- Horizon Pharma Plc
- Immunicum AB
- Jiangsu Hengrui Medicine Co.
- Ltd.
- Kolltan Pharmaceuticals
- Inc.
- Natco Pharma Limited
- Nerviano Medical Sciences S.r.l.
- Novartis AG
- Omeros Corporation
Gastrointestinal Stromal Tumor (GIST) Drug Market, By Type
- Amcasertib
- Anagrelide hydrochloride CR
- APG-1351
- Binimetinib
- Others
Gastrointestinal Stromal Tumor (GIST) Drug Market, By Application
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table Of Contents
Table of Contents
Global Gastrointestinal Stromal Tumor (GIST) Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Gastrointestinal Stromal Tumor (GIST) Drug Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Amcasertib Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Anagrelide hydrochloride CR Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 APG-1351 Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Binimetinib Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Type
8.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.4 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Ariad Pharmaceuticals, Inc.
9.1.1 Ariad Pharmaceuticals, Inc. Profiles
9.1.2 Ariad Pharmaceuticals, Inc. Product Portfolio
9.1.3 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.1.4 Ariad Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.2 Arog Pharmaceuticals, Inc.
9.2.1 Arog Pharmaceuticals, Inc. Profiles
9.2.2 Arog Pharmaceuticals, Inc. Product Portfolio
9.2.3 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.2.4 Arog Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.3 Array BioPharma Inc.
9.3.1 Array BioPharma Inc. Profiles
9.3.2 Array BioPharma Inc. Product Portfolio
9.3.3 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.3.4 Array BioPharma Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.4 Astex Pharmaceuticals, Inc.
9.4.1 Astex Pharmaceuticals, Inc. Profiles
9.4.2 Astex Pharmaceuticals, Inc. Product Portfolio
9.4.3 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.4.4 Astex Pharmaceuticals, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.5 Blueprint Medicines Corporation
9.5.1 Blueprint Medicines Corporation Profiles
9.5.2 Blueprint Medicines Corporation Product Portfolio
9.5.3 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.5.4 Blueprint Medicines Corporation Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.6 Boston Biomedical, Inc.
9.6.1 Boston Biomedical, Inc. Profiles
9.6.2 Boston Biomedical, Inc. Product Portfolio
9.6.3 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.6.4 Boston Biomedical, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.7 Calithera Biosciences, Inc.
9.7.1 Calithera Biosciences, Inc. Profiles
9.7.2 Calithera Biosciences, Inc. Product Portfolio
9.7.3 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.7.4 Calithera Biosciences, Inc. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.8 Chipscreen Biosciences Ltd
9.8.1 Chipscreen Biosciences Ltd Profiles
9.8.2 Chipscreen Biosciences Ltd Product Portfolio
9.8.3 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.8.4 Chipscreen Biosciences Ltd Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.9 Deciphera Pharmaceuticals, LLC
9.9.1 Deciphera Pharmaceuticals, LLC Profiles
9.9.2 Deciphera Pharmaceuticals, LLC Product Portfolio
9.9.3 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.9.4 Deciphera Pharmaceuticals, LLC Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.10 F. Hoffmann-La Roche Ltd.
9.10.1 F. Hoffmann-La Roche Ltd. Profiles
9.10.2 F. Hoffmann-La Roche Ltd. Product Portfolio
9.10.3 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Business Performance
9.10.4 F. Hoffmann-La Roche Ltd. Gastrointestinal Stromal Tumor (GIST) Drug Business Development and Market Status
9.11 Horizon Pharma Plc
9.12 Immunicum AB
9.13 Jiangsu Hengrui Medicine Co., Ltd.
9.14 Kolltan Pharmaceuticals, Inc.
9.15 Natco Pharma Limited
9.16 Nerviano Medical Sciences S.r.l.
9.17 Novartis AG
9.18 Omeros Corporation
10 World Gastrointestinal Stromal Tumor (GIST) Drug Market Assessment by Players
10.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Gastrointestinal Stromal Tumor (GIST) Drug Price (USD/Unit) of Players 2014-2020
10.4 Global Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.1.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.1.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.1.4 North America Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.2.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.2.4 Europe Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.4.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.4.3 South America Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.4.4 South America Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.2.2 North America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.2.3 North America Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.3.2 Europe Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.3.3 Europe Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.4.2 South America Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.4.3 South America Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Gastrointestinal Stromal Tumor (GIST) Drug Sales & Revenue Forecast 2021-2026
14.1 World Gastrointestinal Stromal Tumor (GIST) Drug Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Gastrointestinal Stromal Tumor (GIST) DrugSales and Market Share by Regions
14.1.2 World Gastrointestinal Stromal Tumor (GIST) DrugRevenue and Market Share by Regions
15 Asia Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Amcasertib
15.1.2 Anagrelide hydrochloride CR
15.1.3 APG-1351
15.1.4 Binimetinib
15.1.5 Others
15.2 Consumption Forecast by Application, 2021-2026
16 North America Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Amcasertib
16.1.2 Anagrelide hydrochloride CR
16.1.3 APG-1351
16.1.4 Binimetinib
16.1.5 Others
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Amcasertib
17.1.2 Anagrelide hydrochloride CR
17.1.3 APG-1351
17.1.4 Binimetinib
17.1.5 Others
17.2 Consumption Forecast by Application, 2021-2026
18 South America Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Amcasertib
18.1.2 Anagrelide hydrochloride CR
18.1.3 APG-1351
18.1.4 Binimetinib
18.1.5 Others
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Gastrointestinal Stromal Tumor (GIST) Drug Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Amcasertib
19.1.2 Anagrelide hydrochloride CR
19.1.3 APG-1351
19.1.4 Binimetinib
19.1.5 Others
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Gastrointestinal Stromal Tumor (GIST) Drug Price (USD/Unit) Trend 2021-2026
20.2 Global Gastrointestinal Stromal Tumor (GIST) Drug Gross Profit Trend 2021-2026
21 Conclusion